Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02695095 · ClinicalTrials.gov registry record
Acute Liver Injury in Patients on Dapagliflozin
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 424,091
- Enrollment target
NCT02695095: Completed study, sponsored by AstraZeneca.
NCT02695095 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 424,091 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02695095 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 424,091 participants
- Enrollment target
Study Summary
To compare, by insulin use at the index date, the incidence of hospitalization for acute liver injury (ALI) among patients with type 2 diabetes mellitus who are new users of dapagliflozin with those who are new users of antidiabetic drugs (ADs) in classes other than sodium-glucose cotransporter 2 (SGLT2) inhibitors, insulin monotherapy, metformin monotherapy, or sulfonylurea monotherapy.
Primary Outcome
Patients will be followed from their index date (date of first study drug prescription or dispensing) until they experience one of the following: an event under study, end of time at risk for index medication, death, addition of a non-dapagliflozin (up to six years)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 424,091 participants |
| Start Date | 2017-01-01 |
| Est. Completion | 2020-11-30 |
What the finished NCT02695095 record still lists
NCT02695095 is an observational study that tracks outcomes without assigning an intervention. Its 424,091 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT02695095 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02695095 about?
NCT02695095 is a clinical study titled "Acute Liver Injury in Patients on Dapagliflozin". To compare, by insulin use at the index date, the incidence of hospitalization for acute liver injury (ALI) among patients with type 2 diabetes mellitus who are new users of dapagliflozin with those who are new users of antidiabetic drugs (ADs) in classes other than sodium-glucose cotransporter 2 (S...
What is the current status of trial NCT02695095?
This trial is currently completed. The enrollment target is 424,091 participants. The study started on 2017-01-01. Estimated completion is 2020-11-30.
Who is sponsoring clinical trial NCT02695095?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06342375 · 425,000 participants · NA
Enrollment Barriers, Procedural Denials, and Loss of Medicaid Coverage
- NCT06934239 · 400,000 participants · Phase 4
A Trial Comparing Screening Mammography With and Without Assistance From Artificial Intelligence for Breast Cancer Detection and Recall Rates in Adult Patients
- NCT05065060 · 500,000 participants
Parkinson Progression Marker Initiative Online (PPMI Online)
- NCT06017687 · 500,000 participants · NA
Data Collection and Evaluation of OptiBP Under Investigational Use
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI